RecruitingPhase 3NCT07500090
A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)
Studying Idiopathic hypersomnia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Harmony Biosciences Management, Inc.
- Principal Investigator
- David Seiden, MDHarmony Biosciences Management, Inc.
- Intervention
- HBS-301 tablet(drug)
- Enrollment
- 248 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2028
Study locations (12)
- Santa Monica Clinical Trials, Santa Monica, California, United States
- PharmDev Research Institute, LLC, Miami, Florida, United States
- Central Florida Pediatric Sleep Disorders Institute (Florida Pediatric Research Institute, LLC), Winter Park, Florida, United States
- NeuroTrials Research Inc., Atlanta, Georgia, United States
- Phillip Nowlin, Stockbridge, Georgia, United States
- St. Luke's Hospital, Sleep Medicine and Research Center, Chesterfield, Missouri, United States
- Clinical Research of Gastonia, Gastonia, North Carolina, United States
- Stern Research Partners, LLC, Huntersville, North Carolina, United States
- David Kudrow, MD, Morrisville, North Carolina, United States
- Respiratory Specialists, Wyomissing, Pennsylvania, United States
- K2 Medical Research, Nashville, Tennessee, United States
- West Virginia University, Morgantown, West Virginia, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07500090 on ClinicalTrials.govOther trials for Idiopathic hypersomnia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06732284Study of Sleep Inertia in Major Depressive Disorder by the Psychomotor Vigilance TaskCentre Hospitalier Universitaire de Nīmes
- RECRUITINGPHASE2NCT07096674A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic HypersomniaCentessa Pharmaceuticals (UK) Limited
- RECRUITINGNANCT07006233A Novel Approach to Manage Symptoms of Narcolepsy and Idiopathic HypersomniaUniversity of Sydney
- RECRUITINGPHASE2NCT06843590A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic HypersomniaAlkermes, Inc.
- RECRUITINGPHASE2NCT06812078A Study of TAK-360 in Adults With Idiopathic HypersomniaTakeda
- RECRUITINGPHASE2, PHASE3NCT06767683A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic HypersomniaAlkermes, Inc.
- RECRUITINGPHASE2NCT06752668A Study of ORX750 in Participants With Narcolepsy and Idiopathic HypersomniaCentessa Pharmaceuticals (UK) Limited
- RECRUITINGNANCT06457945Mind-wandering and Predictive Processes in Narcolepsy: a Putative Mechanism Through Covert REM IntrusionsHospices Civils de Lyon